Table 1.
Participant characteristics.
| Items | Sex, male% | Age, y | Weight, kg | Dose, g | #Concentration, mg/L | *Days, d | AST, U/L | ALT, U/L | Cr, μmol/L | eGFR, mL/min |
|---|---|---|---|---|---|---|---|---|---|---|
| Patients treated with VC (n = 25) | ||||||||||
| Average | 68 | 39.00 | 68.42 | 5.99 | 13.46 (n = 36) | 7.03 | 32.83 | 43.91 | 63.68 | 127.72 |
| SD | 14.56 | 14.89 | 1.35 | 8.32 | 2.66 | 33.33 | 35.10 | 16.32 | 30.12 | |
| Min | 19.00 | 43.00 | 2.00 | 3.93 | 5.00 | 7.00 | 6.00 | 44.20 | 58.54 | |
| Max | 75.00 | 100.00 | 10.00 | 34.70 | 15.00 | 106.00 | 118.00 | 112.38 | 215.49 | |
| Median | 38.00 | 69.00 | 5.00 | 10.80 | 6.00 | 22.50 | 32.00 | 64.53 | 128.32 | |
| Patients treated without VC (n = 6) | ||||||||||
| Average | 75 | 35.63 | 75.06 | 2.00 (n = 8) | 23.71 | 44.71 | 75.43 | 105.47 | ||
| SD | 8.52 | 13.82 | 2.08 | 4.79 | 19.91 | 10.64 | 8.79 | |||
| Min | 22.00 | 50.00 | 0.5 (BQL) | 7.00 | 13.00 | 45.96 | 89.98 | |||
| Max | 44.00 | 98.50 | 4.90 | 30.00 | 69.00 | 85.59 | 140.31 | |||
| Median | 38.00 | 98.50 | 0.5 (BQL) | 24.00 | 46.00 | 78.06 | 106.37 | |||
| Healthy (n = 51) | ||||||||||
| Average | 0 | 31.42 | 56.88 | 9.23 | 17.82 | 13.54 | 53.43 | 126.10 | ||
| SD | 6.61 | 5.61 | 5.11 | 3.86 | 7.22 | 7.01 | 19.77 | |||
| Min | 21.00 | 46.80 | 3.09 | 10.00 | 6.00 | 37.98 | 78.54 | |||
| Max | 44.00 | 68.40 | 35.30 | 28.00 | 43.00 | 75.31 | 191.95 | |||
| Median | 31.00 | 55.50 | 8.01 | 12.00 | 17.50 | 52.21 | 128.45 | |||
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; Cr, creatinine; VC, vitamin C.
*
the days from first dosing to blood withdrawal.
#
BQL represents below quantifiable limit, and was recorded as 1/2 LLOQ.